



OFFICE OF THE PROVOST
Office of Compliance Assistance
9500 Old Main Hill
Logan UT 84322-9500
Telephone: (435) 797-8305
FAX: (435) 797-3769

March 26, 2007

Mr. Edward Hammer
The Sunshine Project
1920 Stuart Street
Berkeley, CA 94703

RE: IBC meeting minutes

Dear Mr. Hammond:

Previously, USU has released to you minutes from earlier meetings of USU's Institutional Biosafety Committee (IBC). We herewith provide minutes from all subsequent meetings through the present. In the future if you desire to receive additional meeting minutes, please specify dates that do not overlap with previous requests to which we have responded.

Sincerely,

A handwritten signature in black ink, appearing to read "Russ Price", with a stylized flourish at the end.

Russ Price
Federal Compliance Manager

c: Michelle Johnson-Lancaster, IBC Coordinator, OBA
Craig Simper, General Counsel, USU
John Morrey, IBC Chair, USU



Minutes
Institutional Biosafety Committee
Thursday, June 16, 2005
VSB 3rd floor conference room – 11:30 AM
Page 1 of 2

Present

John Morrey, Chair (voting member)
Anne Anderson (voting member)
Salam Awada (voting member)
Kirt Poulsen (voting member)
Jim Davis (voting member)
Russ Price (ex-officio)
Janet Roberts

Absent

Vernon Summers (voting member)

- With a quorum of Committee members present, the meeting convened and was brought to order at 11:45 AM by John Morrey, Chair. Lunch was provided.
- Dennis Odell was replaced on the Committee by Dr. Jim Davis, MD who is the Director of the Health and Wellness Center on campus.
- John reviewed the IBC SOPs with the Committee.
- Review and vote on 4 Recombinant DNA/RNA registrations using the guidelines found in <http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html>
 - a. **Daryll DeWald** – *Transformation of Arabidopsis plants with cellular protein genes to study plant stress acclimation* -- Proposed by PI to be at BL-1. Approved by Committee at BL-1P. Anne made the motion to approve. Salam seconded. Unanimous.
 - b. **Brett A. Adams** – *Express various signaling proteins in a mammalian cell line or in primary cultures of neuronal cells...* -- Approved by Committee at BL-1. Jim made the motion to approve. Anne seconded. Unanimous.
 - c. **Brett A. Adams** – *Maintain a breeding colony of mice in which the gene encoding CaV2.3, a voltage-gated calcium channel, has been disrupted...* -- Approved by Committee at BL-1N pending changing the housing location of the mice to the LARC. Salam made the motion to approve. Jim seconded. Unanimous.
 - d. **Dale L. Barnard** -- *Evaluating Transgenic and knockout mice* – Approved by Committee at BL1-N for holding and propagating the mice only. John made the motion to approve. Salam seconded. Unanimous.
- Discussion/explanation on 4 Recombinant DNA/RNA registrations using the guidelines found in <http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html>.



Minutes
Institutional Biosafety Committee
Thursday, June 16, 2005
VSB 3rd floor conference room – 11:30 AM
Page 2 of 2

These 4 registrations were tabled for one month to give the Committee time to review the material and then come back prepared to discuss and vote.

- a. **John Morrey** – *Polymerase chain reactions with no vector cloning*
 - b. **John Morrey** – *Subcloning into Escherichia coli K-12 host-vector 1 systems (EK1) with less than 50% viral sequences*
 - c. **John Morrey** – *Plasmid clones of viruses*
 - d. **John Morrey** – *Infectious virus from molecular clones*
- Biotech fermentation inspection was reported by John Morrey
 - Russ Price explained the new DNA database to the committee. It was very well received. He also shared the letter which Brent Miller, VP Research, received from the OBA to USU for its prompt response and attention to OBA's concerns and its compliance with the *NIH Guidelines for Research Involving Recombinant DNA Molecules*.
 - The following action items were assigned:
 - a. Anne will visit the Roundup-Ready alfalfa project (Ralph Whitesides -- SLC)
 - b. Vernon will visit the Roundup-Ready blue grass project (Paul Johnson)
 - c. John will work on the methods and upgrading of annual inventories
 - John made the Committee aware that the Agricultural Experiment Station is requiring their investigators to receive approval from the IBC.
 - The meeting adjourned at 1:15 PM.

Janet Roberts
IBC Administrator



Minutes
Institutional Biosafety Committee
Thursday, August 18, 2005
VSB 3rd floor conference room – 11:30 AM
Page 1 of 3

Present

John Morrey, Chair (voting member)
Anne Anderson (voting member)
Vernon Summers (voting member)
Jim Davis (voting member)
Russ Price (ex-officio) arrived at 12:20

Absent

Kirt Poulsen (voting member)
Salam Awada (voting member)
Janet Roberts

- With a quorum of Committee members present, the meeting convened and was brought to order at 11:35 AM by John Morrey, Chair.
- Discussion and approval of minutes of June 16, 2005 meeting
- Review of Annual Report (copy distributed to members) indicating committee membership and credentials. No action items resulted.
- Discussion of deregulation of Roundup Ready alfalfa project. Copies of electronic communications documenting the deregulation discussion were distributed and discussed. The USU IBC no longer has oversight responsibilities for this project. No action items resulted.
- Vernon Summers reported on his project site inspection of the Roundup Ready Bluegrass project of Paul Johnson. He said that the transgenic plants were cultivated where they were supposed to be and that there was some weed control. No action items resulted.
- Discussion was held to determine the best methods for annual review of ongoing research projects. It was determined by the committee that each project should have an annual review. Possible outcomes of the review could be:
 - a) project reviewed and recommended for continuance or
 - b) project reviewed and recommended for clarification.
 - c) project reviewed and suspended pending clarification or modification.
 - d) project no longer active, terminated.

Motion by Vernon to review projects annually in this manner, second by John.
Unanimous in favor.

- The following projects were reviewed in the Annual Review process:



Minutes
Institutional Biosafety Committee
Thursday, August 18, 2005
VSB 3rd floor conference room – 11:30 AM
Page 2 of 3

- a. **Anne Anderson** – *Cloning and promoter fusion assays in native host or E. coli disarmed strains: PCR detection of RNA produced in the bacterial cells.* This was reviewed and approved for continuance at BL1 containment. Motion to approved: John; Second: Vernon. Unanimous in favor.
 - b. **Bart Weimer** – *Functional Genomics.* This was reviewed and approved at for continuance at BL1 containment. Motion to approve: Anne; Second: John; Unanimous in favor.
 - c. **Bradley Kropp** – *PCR product amplification.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; Second: Vernon; Unanimous in favor.
 - d. **Dennis Welker and Joanne Hughes** – *Genetic analysis of bacteria, including lactic acid bacteria, fungi, and dictyostelium species.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: Jim; Second: Vernon; Unanimous in favor.
- John Morrey had five projects for annual review. Because there was not a quorum present when he recused himself from the discussion, these items would require action in the next committee meeting:

Project 1: *Subcloning into Escherichia coli K-12 Host-Vector 1 Systems (EK1) with less than 50% viral sequences;* This was reviewed and recommended for approval for continuance at BL1 containment; No vote due to lack of quorum.

Project 2: *Polymerase chain reactions with no vector cloning.* This was reviewed and recommended for approval for continuance at BL1 containment; No vote due to lack of quorum

Project 3: *Plasmid clones of viruses.* This was reviewed and recommended for approval for continuance at BL2 containment for HBV and WNV; No vote due to lack of quorum

Project 4: *Transgenic mice carrying the infectious clone of hepatitis B virus (HBV),* previously approved at BL3-N. Discussion regarding a wild Coronavirus in LARC rooms with special need to sequester breeding groups of animals that are not available via outside vendors. This was reviewed and recommended for approval for continuance at a change in isolation level form



Minutes
Institutional Biosafety Committee
Thursday, August 18, 2005
VSB 3rd floor conference room – 11:30 AM
Page 3 of 3

BL3-N to BL2-N; NIH Guidelines in concurrence with this change. No vote due to lack of quorum

Project 5: *Infectious virus from molecular clones*. This was reviewed and recommended for approval for continuance at BL2 containment for HBV and BL-3 for WNV; No vote due to lack of quorum

- The following action item was assigned:
 - a. Russ Price indicated the Office of Compliance Assistance in cooperation with the VPR would make a website dedicated to the IBC available, and agreed to include a copy of the "Recombinant DNA/RNA Registration Form."
- Meeting adjourned at 12:45 pm. Next meeting time and location to be announced.



Minutes
Institutional Biosafety Committee
Thursday, October 13, 2005
VSB 3rd floor conference room – 11:30 AM
Page 1 of 6

Present

John Morrey, Chair (voting member)
Anne Anderson (voting member)
Vernon Summers (voting member)
Russ Price (ex-officio)
Kirt Poulsen (voting member)
Salam Awada (voting member)
Janet Roberts

Absent

Jim Davis (voting member)

- With a quorum of Committee members present, the meeting convened and was brought to order at 11:35 AM by John Morrey, Chair.
- Minutes of August 18, 2005 meeting: Motion to approve: John; second: Vernon. Voting was unanimous in the affirmative.
- The following projects/activities were reviewed in the Annual Review process then voted on in John Morrey's absence:

Motion to approve: Vernon; second: Salam. Voting was unanimous in favor of approval.

- John Morrey** – *Subcloning into Escherichia coli K-12 Host – Vector 1*. This was reviewed and approved for continuance at BL1 containment.
 - John Morrey** – *Polymerase chain reactions with no vector cloning*. This was reviewed and approved for continuance at BL1 containment.
 - John Morrey** – *Transgenic mice carrying the infectious clone of hepatitis B virus (HBV)*. This was previously approved BL3-N. This was reviewed and approved for continuance at BL2 containment.
 - John Morrey** – *Plasmid clones of viruses*. This was reviewed and approved for continuance at BL2 containment for HBV and WNV.
 - John Morrey** – *Infectious virus from molecular clones*. This was reviewed and approved for continuance at BL2 containment for HBV and BL3 for WNV.
- The following new projects/activities were reviewed:
 - Ramona Skirpstunas** – *PCR subcloning or expressing of animal, plant or prokaryotic sequences*. This was reviewed and approved for continuance at



Minutes
Institutional Biosafety Committee
Thursday, October 13, 2005
VSB 3rd floor conference room – 11:30 AM
Page 2 of 6

- BL1 containment. Motion to approve: Ann; second: Salam. Unanimous in favor of approval.
- b. **Ilka Nemere** – *Subcloning or PCR of eukaryotic, prokaryotic*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: Vernon; second: Kirt. Unanimous in favor of approval.
 - c. **Ilka Nemere** – *Transgenic mice*. This was reviewed and approved for continuance at BL1-N containment. Motion to approve: Ann; second: John. Unanimous in favor of approval.
 - d. **Paul Cliften** – *PCR and subcloning bacteria, yeast, plant or animal sequences*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: Kirt; second: Salam. Unanimous in favor of approval.
 - e. **Katarina Stroffekova** – *Subcloning, point mutations, transfections of cell cultures (primary culture of myotubes and DRG neurons, HEK cell line)*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Vernon. Unanimous in favor of approval.
 - f. **Katarina Stroffekova** – *Transgenic mice*. This was reviewed and approved for continuance at BL1-N containment. Motion to approve: John; second: Kirt. Unanimous in favor of approval.
- The following simple BL1 projects/activities were reviewed in the Annual Review process
 - a. **Thomas Baldwin** – *PCR and subcloning into plasmids*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Ann. Unanimous in favor of approval.
 - b. **Dale Barnard** – *PCR and subcloning into plasmids*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: Vernon; second: Kirt. Unanimous in favor of approval.
 - c. **Roger Coulombe** – *PCR or subcloning animal, plant or prokaryotic*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: Ann; second: Salam. Unanimous in favor of approval.
 - d. **Daryll Dewald** – *PCR and subcloning animal, plant or prokaryotic*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: Kirt; second: Salam. Unanimous in favor of approval.



Minutes
Institutional Biosafety Committee
Thursday, October 13, 2005
VSB 3rd floor conference room – 11:30 AM
Page 3 of 6

- e. **Scott Ensign** – *PCR and cloning animal, plant or prokaryotic sequences.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: Ann; second: Vernon. Unanimous in favor of approval.
- f. **Brian Gowen** – *Subcloning or PCR of eukaryotic, prokaryotic or viral sequences.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Kirt. Unanimous in favor of approval.
- g. **Doug Harris** – *PCR amplification of DNA and restriction digestion of DNA.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Salam. Unanimous in favor of approval. Discussion: Since Doug's students collect their own cells for genetic analysis, he will need to be given IRB follow-up. The class uses PCR to characterize genetically plants available on the market, so they are of no concern to the committee because they are approved for commercial use.
- h. **Joan Hevel** – *Subcloning or PCR of animal, plant, yeast or bacteria sequences.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Vernon. Unanimous.
- i. **Joseph Li** – *Subcloning of viral sequences or animal, plant or bacterial sequences.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: Ann; second: Kirt. Unanimous in favor of approval.
- j. **Jeanette Norton** – *Cloning or PCR of plant or prokaryotic sequences.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: Ann; second: John. Unanimous in favor of approval.
- k. **Lee Rickords** – *Induced apoptosis in ductal carcinoma cells.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Vernon. Unanimous in favor of approval.
- l. **Peter Ruben** – *PCR and subcloning eukaryotic sequences.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: Ann; second: Kirt. Unanimous in favor of approval.
- m. **Lance Seefeldt** – *PCR and subcloning prokaryotic sequences.* This was reviewed but approval was withheld pending clarification on large-scale production (BL1 containment). John will follow up. Motion to clarify: Ann; second: Kirt. Unanimous in favor of clarification.
- n. **Ken White** – *Subcloning or PCR of eukaryotic, prokaryotic.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: Ann; second: Kirt. Unanimous in favor of approval.



Minutes
Institutional Biosafety Committee
Thursday, October 13, 2005
VSB 3rd floor conference room – 11:30 AM
Page 4 of 6

- o. **Quinton Winger** – *Subcloning or PCR of eukaryotic, prokaryotic*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Kirt. Unanimous in favor of approval.
 - p. **Paul Wolf** – *Subcloning or PCR of eukaryotic, prokaryotic*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: Vernon; second: Ann. Unanimous in favor of approval.
 - q. **Yajun Wu** – *Subcloning or PCR of eukaryotic, prokaryotic*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: Ann; second: Salam. Unanimous in favor of approval.
- The following Exempt projects/activities were reviewed in the Annual Review process:
 - a. **John Carman** – *Mapping and cloning plant genes*. This was reviewed and approved for continuance as Exempt. Motion to approve: John; second: Ann. Unanimous in favor of approval.
 - b. **Noelle Cockett** – *PCR and subcloning animal sequences*. This was reviewed and approved for continuance at BL-1. Motion to approve: Ann; second: John. Unanimous in favor of approval. Discussion: Noelle requested the activity to be Exempt which the IBC will be pleased to re-evaluate if she were to identify the exact host and vectors for their names and acronyms.
 - c. **Quinton Winger** – *Transgenic mice*. Approval withheld until receive clarification. Motion to clarify: Ann; second: Kirt. Unanimous in favor of clarification. Discussion: The IBC requests clarification on this activity. III F-4 does not appear to identify your activity as Exempt. III D-F c(2) appears to apply to the project. IBC needs to know from where these animals were purchased.
 - d. **Paul Wolf** – *Genetics teaching lab (BIOL 4100)*. This was reviewed and approved for continuance as Exempt. Motion to approve: John; second: Ann. Unanimous in favor of approval.
 - e. **Jeff Broadbent** – *Genetic analysis of bacteria, including lactic acid bacteria and PCR*. Approval withheld until receive clarification. Motion to clarify: John; second: Kirt. Unanimous in favor of clarification. John asked Ann to obtain the clarification.
 - f. **Ron Sims** – *PCR and subcloning of prokaryotic sequences*. This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Salam. Unanimous in favor of approval.



Minutes
Institutional Biosafety Committee
Thursday, October 13, 2005
VSB 3rd floor conference room – 11:30 AM
Page 5 of 6

- g. **Mike Pfrender** – *PCR or subcloning plant, animal, prokaryotic sequences.* This was reviewed and approved for continuance at BL1 containment. Motion to approve: John; second: Salam. Unanimous in favor of approval.
- The following people were discussed as no longer having active projects/activities (no vote needed):
 - a. **Emily Harrington** – Emily has moved from the area.
 - b. **Bill Kemp** – Bill has moved from the area.
 - c. **Jon Takemoto** – Jon's lab is not currently doing research or work involving recombinant DNA, nor does he anticipate doing any in the near future.
 - d. **Kytai Nguyen** – Kytai has moved from the area.
 - e. **Charles E. Carpenter** – Charles has discontinued such research.
 - f. **David Hole** – David does not currently have recombinant DNA projects.
 - g. **Michelle Grilley** – Michelle is not currently conducting any recombinant DNA work.
 - h. **Paul Johnson** – Paul's field trial with the Scott's Company is terminated and not be continued.
- The following projects/activities using transgenic plants were reviewed in the Annual Review process:
 - a. **Daryll Dewald** – *Transgenic plant with green fluorescing protein.* This was reviewed and approved for continuance at BL1-P containment. Motion to approve: John; second: Ann. Unanimous in favor of approval.
 - b. **Paul Johnson** – *Transgenic Poa pratensis and poa spp. lines.* No action was taken. Approval withheld pending clarification. Ann will follow up.
 - c. **Keith Mott** – *Transgenic Tobacco plants.* No action was taken. Approval withheld pending clarification. Ann will follow up.
 - d. **Yajun Wu** – *Transgenic plants.* This was reviewed and approved for continuance at BL1-P containment. Motion to approve: John; second: Ann. Unanimous in favor of approval.
- The following project/activity using transgenic animals was reviewed in the Annual Review process:
 - a. **Brian Gowen** – *Transgenic mice.* This was reviewed and approved for continuance at BL1-N containment. Motion to approve: John; second: Kirt. Unanimous in favor of approval.



Minutes
Institutional Biosafety Committee
Thursday, October 13, 2005
VSB 3rd floor conference room – 11:30 AM
Page 6 of 6

- The following BL2 project/activity was reviewed using the Annual Review process:
 - a. **Dale Barnard** – *Infectious viral sequences – parainfluenza virus*. This was reviewed and approved for continuance at BL2 containment (human parainfluenza virus). Motion to approve: Vernon; second: Kirt. Unanimous in favor of approval.
- The following project/activity was reviewed using the Annual Review process:
 - a. **Linda Powers/Walther Ellis** – *PCR or subcloning plant, animal, prokaryotic, viral sequences (not Select Agent)*. No action was taken. Approval withheld pending clarification. John will follow up.
- Action items:
 - a. Ann will follow up with Jeff Broadbent, Paul Johnson, and Keith Mott.
 - b. John will follow up with Lance Seefeldt, Bart Weimer and Mark Signs, Quinton Winger, and Linda Powers/Walther Ellis.
- Meeting adjourned at 1:15 pm. Next meeting time and location to be announced.



Minutes
Institutional Biosafety Committee
Monday, November 7, 2005
Telephone conference – 10:00 AM
Page 1 of 2

Present

John Morrey, Chair (voting member)
Kirt Poulsen (voting member)
Vernon Summers (voting member)
Salam Awada (voting member)
Russ Price (ex-officio)
Janet Roberts

Absent

Jim Davis (voting member) excused
Anne Anderson (voting member) excused

- With a quorum of Committee members present, the telephone conference convened and was brought to order at 10:10 AM by John Morrey, Chair.
- The following projects/activities were reviewed and discussed at the last meeting of the committee on 10-13-05 but the vote was delayed pending further clarification. Information was presented on the projects as follows:
 - a. **Lance Seefeldt** – *PCR and subcloning prokaryotic sequences*. The project calls for the production of quantities of nitrogenase that exceed 10 liters. It has been confirmed that the work is to be done in the Biotech Center. However, the Biotech Center facilities have not yet been approved for large quantity production. John moved that the activity be approved for Lance, but that a memo be sent to the Biotech Center requiring that planned equipment installation be carried out prior to the work commencing in its facility. The activity was reviewed and approved for continuance at BL1-L containment. Motion to approve: John; second: Kirt. Unanimous in favor of approval.
 - b. **Quinton Winger** – *Transgenic mice*. Quinton had made a request to have this activity approved as exempt. John discussed the request with Quinton. In light of the fact that the mice will be kept at the LARC, where animals are routinely handled under BL1-N requirements, approval at that level would not impact his activity. This was reviewed and approved for continuance at BL1-N containment. Motion to approve: John; second: Vernon. Unanimous in favor of approval.
 - c. **Paul Johnson** – *Transgenic Poa pratensis and poa spp. lines*. This was reviewed and approved for continuance at BL1-P containment (activities taking place in the locked cold frame and the green house). Motion to approve: Vernon; second: Salam. Unanimous in favor of approval.



Minutes
Institutional Biosafety Committee
Monday, November 7, 2005
Telephone conference – 10:00 AM
Page 2 of 2

- d. **Keith Mott** – *Transgenic Tobacco plants*. This was reviewed and approved for continuance at BL1-P containment. Motion to approve: John; second: Vernon. Unanimous in favor of approval.
- The following projects/activities remained tabled, and will be discussed at the next meeting:
 - a. **Jeff Broadbent** – *Genetic analysis of bacteria, including lactic acid bacteria and PCR*. Ann will follow up.
 - b. **Linda Powers/Walther Ellis** – *PCR or subcloning plant, animal, prokaryotic, viral sequences (not Select Agent)*. John will follow up.
- Action items:
 - a. Ann will follow up with Jeff Broadbent
 - b. John will follow up with Linda Powers/Walther Ellis.
 - c. Correspondence will be sent to Bart Weimer and Mark Signs with a cc to Lance Seefeldt. The memo will outline existing conditions that preclude large-quantity production in the Biotech Center facilities, and needed steps to be taken to comply with the DNA Guidelines prior to initiating Lance's project.
 - d. Letter will be sent to Noelle Cockett indicating that her project was approved at BL1 and not Exempt.
- Telephone conference adjourned at 10:20 AM. Next meeting time and location to be announced.

Janet Roberts



Minutes
Institutional Biosafety Committee
Tuesday, March 14, 2006
VSB Conference Room 302, 4:00 pm
Page 1 of 2

Present

John Morrey, Chair (voting member)
Jim Davis (voting member)
Kirt Poulsen (voting member)
Vernon Summers (voting member)
Anne Anderson (voting member)
Russ Price (ex-officio)
Janet Roberts

Absent

Salam Awada (voting member) excused

- With a quorum of Committee members present, the meeting convened and was brought to order at 4:05 pm by John Morrey, Chair.
- Minutes of November 7, 2005, phone conference: Motion to approve: John; second: Kirt. Voting was unanimous in the affirmative to accept minutes as written.
- The following project/activity was reviewed and discussed at the last meeting of the committee (via phone conference) on 11/7/2005 but the vote was delayed pending further clarification. Information was presented on the project as follows:
 - a. **Walther Ellis/Linda Powers** – *PCR and subcloning bacteria and viruses formerly called PCR or subcloning plant, animal, prokaryotic, viral sequences*). Discussion ensued as to whether this should be approved at a BL-1 or BL-2. Since the PI recommends a BL-2 containment and is expecting to maintain that containment level, the project was approved at BL-2. "Biosafety level" was explained and its effect on security rather than containment levels was discussed. The activity was reviewed and approved at BL-2 containment. Motion to approve: Jim; second: Vernon. Unanimous in favor of approval.
- The following project/activity was tabled (pending further clarification), and will be discussed at the next meeting:
 - a. **Jeff Broadbent** – *Genetic analysis of bacteria, including lactic acid bacteria and PCR*. Ann will follow up in clarifying with Jeff the possibility that not all the work described on his registration form is exempt and so may fall under BL-1.



Minutes
Institutional Biosafety Committee
Tuesday, March 14, 2006
VSB Conference Room 302, 4:00 pm
Page 2 of 2

- The following new project was reviewed:
 - a. **Jessie D. Trujillo** – *Cloning and expression of subgenomic mammalian and CAEV sequences*. This was reviewed and approved at BL-1 containment. Motion to approve: John; Second: Jim. Unanimous in favor of approval. Discussion: Asked if the PI would be making CAEV viruses. It was determined through a phone call to the PI that there would be no chimeric CAEV viruses made.
- Miscellaneous Discussion:
 - a. Russ reviewed the data base, its format and progress.
 - b. Jim suggested that we add the registration form to the data base as a jpg and to implement the use of Network Attached Storage to allow protected access by the committee.
- Action items:
 - a. Ann will follow up with Jeff Broadbent
 - b. John will look through the regulations to clarify the difference between Exempt and BL-1 status (re Jeff Broadbent's activity).
- Committee meeting adjourned at 4:50 pm. Next meeting time and location to be announced.

Janet Roberts



Minutes
Institutional Biosafety Committee
Friday, June 16, 2006
VSB Conference Room 302, 10:00 am
Page 1 of 5

Present

John Morrey, Chair (voting member)
Jim Davis (voting member)
Kirt Poulsen (voting member)
Vernon Summers (voting member)
Anne Anderson (voting member) arrived 11:15
Salam Awada (voting member)
Russ Price (ex-officio)
Janet Roberts

Absent

- With a quorum of members present, the open committee meeting convened and was brought to order at 10:00 am by John Morrey, Chair.
- Minutes of March 14, 2006 committee meeting: Motion to approve: Vernon; second: Kirt. Voting was unanimous in the affirmative to accept minutes as written.
- Using a letter from the NIH OBA (dated 5/14/2004) the substance of minutes in general was reviewed by John and discussed by the committee. Major points in the letter were as follows: public access to IBC minutes, redacting information from minutes.
- There were no new activities to be reviewed by the committee.
- Annual NIH OBA Report of USU IBC committee members due in August, 2006 with updated biographical sketches of each member.
- Annual review process:
 - a. It was emphasized that activities do not have a default expiration date, but are reviewed annually to determine if an activity has been discontinued or should be modified or terminated.
 - b. John presented a draft of the annual review form letter. A few words were changed to add clarity. Review procedures were discussed. Russ and Kirt will review the regulations and return to the committee with a recommendation concerning review of activities used in multiple projects.
 - c. Copies of approval letters for the annual review will be emailed to each PI. John will work with Janet in getting these letters out.



Minutes
Institutional Biosafety Committee
Friday, June 16, 2006
VSB Conference Room 302, 10:00 am
Page 2 of 5

- Review of database (DB) progress.
 - a. Russ added two more fields to the report generated by the DB: IBC #, Risk Assessment Criteria (formerly "High Risk Level")
 - b. Janet will generate annual approval letters from the DB
- Biohazards Committee
 - a. The Biohazards Committee has oversight of biological experimentation that does not involve recombinant DNA. Primarily, it regulates infectious diseases
 - b. In discussing the purpose of this committee, members of the committee felt that it would better to maintain Biohazards as a separate committee rather than be combined with IBC.
- Action items:
 - a. John will modify the annual review form letter
 - b. Russ will take out the option of "None" in the Risk Assessment Criteria in the database
 - c. Russ and Kirt will review the regulations and return to the committee with a recommendation concerning review of activities used in multiple projects.
- Committee meeting adjourned at 11:20 am. Motion: John; Second: Vernon
Next meeting time and location to be announced.

Janet Roberts



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Office of Biotechnology Activities
National Institutes of Health
6705 Rockledge Drive
Suite 750, MSC 7985
Bethesda, MD 20892-7985
(301) 496-8838 (Phone)
(301) 496-8839 (Fax)
<http://www4.od.nih.gov/oba/>

May 14, 2004

TO: Members and Staff of Institutional Biosafety Committees

FROM: Amy P. Patterson, M.D. *AP*
Director
NIH Office of Biotechnology Activities

SUBJECT: Minutes of Institutional Biosafety Committee Meetings

Recently, the NIH Office of Biotechnology Activities has received a number of queries concerning preparation of, and public access to, minutes of Institutional Biosafety Committee (IBC) meetings.

Minute-taking is an aspect of IBC administration that the *NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)* do not prescribe in detail. In this and other areas, institutions are accorded latitude to develop specific procedures and practices that are in keeping with their local circumstances and organizational considerations, as well as the overall spirit and intent of the *NIH Guidelines*. In doing so, however, it is also paramount that institutions apply sound judgment and consistent practices.

To assist institutions in developing policies and practices for the preparation of IBC meeting minutes that are in keeping with the intent of the *NIH Guidelines* and that are acceptable to the NIH, we have prepared the attached questions and answers. We also have posted this information to the IBC page on our Web site: <http://www4.od.nih.gov/oba/IBC/IBCindexpg.htm>.

If you have any questions about this material, do not hesitate to contact Allan C. Shipp, Director of Outreach, NIH Office of Biotechnology Activities, by email at shippa@od.nih.gov or by telephone at 301-435-2152.

**NIH Office of Biotechnology Activities
Questions and Answers Concerning
Institutional Biosafety Committee (IBC) Meeting Minutes
May 14, 2004**

Preparation of IBC minutes

Q: How detailed should the minutes of IBC meetings be?

A: The *NIH Guidelines* do not prescribe the level of detail that must be captured in IBC meeting minutes. However, there are some generally accepted principles about minute-taking, including the type of information that minutes should capture, that can be found in such references as *Robert's Rules of Order*. In keeping with those principles, minutes should reflect the date and place of the meeting, whether minutes of the prior meeting were approved, individuals in attendance, whether and why the meeting was open or closed, all major motions, major points of order, and whether motions were approved, and the time of meeting adjournment. In general, the minutes should offer sufficient detail to serve as a record of major points of discussion and the committee's rationale for particular decisions, documenting that the IBC has fulfilled its review and oversight responsibilities as outlined under Section IV-B-2-b of the *NIH Guidelines*. Minutes do not need to be transcripts or kept at a level of detail that attributes each remark to a specific individual.

Access to IBC Minutes

Q: What do the *NIH Guidelines* say about public access to minutes of IBC meetings?

A: Section IV-B-2-a-(7) of the *NIH Guidelines* states:

Upon request, the institution shall make available to the public all Institutional Biosafety Committee meeting minutes and any documents submitted to or received from funding agencies which the latter are required to make available to the public.

Q: What documents are encompassed by the language, "...and any documents submitted to or received from funding agencies which the latter are required to make available to the public"?

Under Section IV-B-2-a-(3) of the *NIH Guidelines*, IBCs must submit committee rosters and biographical sketches of members to the NIH. The NIH would be required to disclose that information in response to a request under the federal Freedom of Information Act. Thus, under the *NIH Guidelines*, IBCs are required to make rosters and biographical sketches that have been submitted to NIH available to the public upon request.

Q: May we redact information from these documents before we make them available to the public?

A: Section IV-B-2-a-(6) of the *NIH Guidelines* acknowledges that the protection of private or proprietary information is a legitimate consideration in deciding whether to open IBC meetings to the

public. Since minutes are a record of the meeting, it is logical to extend this concept to information captured in those documents. Institutions may, therefore, redact proprietary or private information, but must do so judiciously and consistently for all requested documents. Articulating criteria for redaction in IBC operating procedures can help promote consistency and proper redaction practices. Some examples of information that may be redacted include trade secret information and other confidential commercial information, home telephone numbers and home addresses of IBC members, and specific information whose disclosure would directly compromise institutional or national security.

Q: Is it acceptable to require that an individual requesting access to IBC minutes come to our institution and view the minutes on site in a reading room?

A: Access to minutes should not be overly burdensome to the public. Requiring a member of the public to travel to the site is generally not appropriate since this can often entail significant time, effort, and travel expenses. There are, however, multiple ways to make minutes available that are relatively unburdensome to both the institution and the requestor. Minutes can be sent by U.S. mail, email or made available on the institution's Web site (either openly, or through special access provided to requestors only).

Q: May we charge the public for copies of our minutes?

A: An institution may charge an amount sufficient to cover the costs of providing minutes. However, charges should not be excessive or used as a deterrent to access.

Q: Who should be considered a member of "the public"? Are private organizations considered members of the public? Is the concept of "public" limited to our neighborhood, city, or state?

A: Since the *NIH Guidelines* are nationally applied, and no limitations were placed on the notion of "public" when they were first promulgated, "public" should be interpreted in its broadest sense - as referring to all people and entities.

Q: We are a state institution and, as an entity of state government, we are required to follow our state public disclosure laws in making institutional documentation publicly available upon request. Is this in conflict with the public access provisions of the *NIH Guidelines*?

A: The *NIH Guidelines* do not preclude institutions from complying with any applicable laws in responding to public requests for IBC minutes. A provision in state law, Federal law, or institutional policy that requires an institution to follow specific procedures in responding to requests for institutional records is not inherently in conflict with any provision of the *NIH Guidelines*. A conflict with the *NIH Guidelines* would occur, however, if any of these laws precluded an institution from providing the minutes altogether. Redaction of certain information is permissible under the *NIH Guidelines*, as discussed above.



Minutes
Institutional Biosafety Committee
Monday, August 7, 2006
VSB Conference Room 302, 1:00 pm
Page 1 of 3

Present

John Morrey, Chair (voting member)
Jim Davis (voting member)
Kirt Poulsen (voting member)
Vernon Summers (voting member)
Anne Anderson (voting member)
Salam Awada (voting member)
Russ Price (ex-officio)
Janet Roberts
Jeff Broadbent (Assoc. VPR)
Quinton Winger (PI)

Absent

- With a quorum of members present, the open committee meeting convened and was brought to order at 1:05 pm by John Morrey, Chair.
- Minutes of June 16, 2006, committee meeting: Motion to approve: Jim; second: Kirt. Voting was unanimous in the affirmative to accept minutes as written.
- The annual report was mailed to the OBA on 7-19-06. A letter of renewal was received back from OBA. Next report due in one year. The date for the next submission is based on the date of the current submission, not a fiscal year.
- John showed an example of the letter that we send to PI's requesting information which is a result of SPO inquiries. (See page 3 of these minutes)
- The analysis of the review process was discussed.
 - John clarified the regulations and explained that the categories of approval are 1) Exempt, and 2) Biocontainment levels 1,2,3,4. Exempt is not the default category. PI must request it.
 - Russ referred the committee to the regulatory analysis handout, in particular Section III-D, of the NIH Guidelines (http://www4.od.nih.gov/oba/rac/guidelines_02/NIH_Guidelines_Apr_02.htm) "Experiments that Require IBC Approval Before Initiation." He also pointed out that there is a section in the "Guidelines" devoted to experiments that can begin simultaneous to submission to the IBC.
 - John moved to find a consultant (second by Jim) that would help the committee determine if correct review and approval procedures were



Minutes
Institutional Biosafety Committee
Monday, August 7, 2006
VSB Conference Room 302, 1:00 pm
Page 2 of 3

being followed and who would also make suggestions for improvement. Extensive discussion followed. Some members and guests felt that approaching peer institutions to try to establish "best practice" might provide more meaningful information. The motion was tabled.

- Annual review process
 - John will work with Janet to send an annual letter to PIs asking them if their activity has changed from the one originally approved. If so, she will send them a new form to complete, sign and return. If not, she will send a copy of the originally-approved form for them to sign and return to her.
- Review of the database progress was tabled for a future discussion.
- The following activities were reviewed by the committee:
 - a. **Jessie Trujillo** – *Utilize as positive control for molecular diagnostic assay development.* This was approved at BL-1 containment. Motion to approve: Jim; Second: John (with qualification). Unanimous in favor of approval. Discussion: The PI will not be using toxin genes as incorrectly indicated on her prior registration form. Sources of the DNA will be prokaryotic or viral purchased or provided from ATTC, CDC, NVSL. Less than 10% of any genomes will be used. The PI will be using E. coli vector systems.
 - b. **Jeff Broadbent** – *Cloning of food grade enzymes from Brevibacterium linens in E. coli.* This was approved at BSL-1 containment. Motion to approve: John; second: Jim. Discussion: Changed status from exempt to not exempt.
- Action items:
 - a. John will make a list of questions to ask institutions and confirm with Russ.
 - b. Russ will make a list of peer institutions for John's inquiry.
 - c. Janet will update Jessie's registration and obtain her signature.
 - d. John will work with Janet in sending out the annual letter to PIs.
- Committee meeting adjourned at 2:45 pm. Motion: John; Second: Vernon
Next meeting time and location to be announced.



Minutes
Institutional Biosafety Committee
Monday, August 7, 2006
VSB Conference Room 302, 1:00 pm
Page 3 of 3

Dear

Are the recombinant DNA/RNA activities of the proposal identified in the memorandum (below) as Proposal Code No. _____ covered in your current approval # _____ with the USU Institutional Biosafety Committee? A copy of your recombinant DNA approval form is attached to assist you in determining the answer to this question.

Please email your response back to me:

_____ Yes, the proposed work is covered by the current IBC approval # ____.

_____ No, the proposed work is NOT covered by the current IBC approval # ____.

Thank you,

Janet

Janet Roberts
Utah State University
IBC Administrator
9530 Old Main Hill
Logan, UT 84322-9530

Military Science 214a
(435) 797-1821
(435) 797-3769 (fax)



Minutes
Institutional Biosafety Committee
Tuesday, October 10, 2006
VSB Conference Room 302, 9:00 am
Page 1 of 2

Present

John Morrey, Chair (voting member)
Kirt Poulsen (voting member)
Vernon Summers (voting member)
Salam Awada (voting member)
Russ Price (ex-officio)
Janet Roberts

Absent

Jim Davis (voting member)
Anne Anderson (voting member)

- With a quorum of members present, the open committee meeting convened and was brought to order at 9:10 am by John Morrey, Chair.
- Minutes of August 7, 2006, committee meeting: Motion to approve: John; second: Kirt. Voting was unanimous in the affirmative to accept minutes as written.
- Annual review process
 - Non-response to request for the annual review update:
 - a. Ron Sims (#58) – Motion by John to inactivate Ron's activity if no response after a 2nd attempt to contact him; 2nd by Kirt. Unanimous in favor of this action. Discussion: It was determined by the committee that a 2nd letter would be mailed to Ron to determine if his activity was performed in Anne's lab or some other. If in Anne's lab, the approval for that lab would suffice. If not, then Ron would need to obtain a new approval.
 - Changes to existing/approved activities:
 - a. Dale Barnard (#56) – Motion by John to approve at containment level BL-2; 2nd by Vernon. Unanimous in favor of approval. Discussion: This was changed from BL-1 due to the change in activity (**From:** infectious viral sequences – parainfluenza virus; **To:** Inserting green fluorescent protein into paramyxoviruses, including human parainfluenzavirus type III, human metapneumovirus, and measles virus)
 - b. John Carman (#38) – Motion by John to approve this as a new activity at containment level BL-1P rather than amend #38 which was previously approved as Exempt; 2nd by Kirt. Unanimous in favor of approval. Discussion: (Changed **from:** Mapping and cloning plant genes **to:** Transformation of *Arabidopsis* with genes from other plants). The former activity would remain active and be kept separate.



Minutes
Institutional Biosafety Committee
Tuesday, October 10, 2006
VSB Conference Room 302, 9:00 am
Page 2 of 2

- c. Paul Johnson (#52) -- Motion by Kirt to approve at containment level BL-2P; 2nd by John. Unanimous in favor of approval. Discussion: The greenhouse facility being used for this work is a BL-2P facility.
- o New recombinant DNA activities
 - a. Lance Seefeldt -- PCR amplification of DNA and restriction digestion of DNA. Motion by John to approve at BL-1. 2nd by Vernon. Discussion: This was determined to be exempt by the committee. John withdrew his previous motion and presented a 2nd motion to approve as exempt; 2nd by Salam. Unanimous in favor of approval
 - b. Dennis Welker -- Cloning specific gene products *Ascosphaera* species into *E. coli* vectors. Motion by John to approve this as exempt. 2nd by Salam. Unanimous in favor of approval. Discussion: It was assumed that Dr. Welker's activity contains no elements that would make it anything other than exempt. However, the appropriate boxes were not checked on his registration. John amended his motion to be provisional in that Dr. Welker's registration form be clearly marked.
- Review of the database progress
 - o Nothing to report
- Action items:
 - o Janet will follow up on annual review
- Committee meeting adjourned at 10:00 am. Next meeting time and location to be announced.

Janet Roberts



Minutes
Institutional Biosafety Committee
Monday, March 5, 2007
VSB Conference Room 302, 11:30 pm
Page 1 of 1

Present

John Morrey, Chair (voting member)
Jim Davis (voting member)
Kirt Poulsen (voting member)
Vernon Summers (voting member)
Janet Roberts
Mike Johnson (Jim Davis job shadow)

Absent

Russ Price (ex-officio)
Anne Anderson (voting member)
Salam Awada (voting member)

- With a quorum of members present, the open committee meeting convened and was brought to order at 11:35 pm by John Morrey, Chair.
- Minutes of October 10, 2006, committee meeting: Motion to approve: Kirt; second: Jim. Voting was unanimous in the affirmative to accept minutes as written.
- The following new recombinant DNA activity was reviewed by the committee:
 - a. **Korry Hintze** – *Gene promoter Characterization*. This was approved at BSL-1 containment. Motion to approve: John; Second: Jim. Unanimous in favor of approval. No discussion.
- Action items:
 - a. Russ will communicate with Kirt regarding possible funding to attend IBC training in San Diego March 25, 2007.
- Committee meeting adjourned at 11:55 am. Next meeting time and location to be announced.

Janet Roberts

the sunshine project

101 West 6th Street, Suite 607 Austin TX 78701 USA

Tel/Fax: +1 512 494 0545

<http://www.sunshine-project.org>

24 May 2004

ADVISORY COMMITTEE

Ignacio Chapela
Berkeley, United States

Chae Yoke Ling
Kuala Lumpur, Malaysia

Julian Perry Robinson
Brighton, United Kingdom

Tewelde Berhan Gebre Egziabher
Addis Ababa, Ethiopia

Christine von Welzsäcker
Bonn, Germany

Mark Wheelis
Davis, United States

GERMAN OFFICE

The Sunshine Project
Scheplerstrasse 78
22767 Hamburg

Tel: +49 40 431 88 001
Fax: +49 40 675 03 988

The Sunshine Project US is a
501(c)3 non-profit organization.
Donations are tax-deductible.

The Sunshine Project Germany
(e.V.) is a federally recognized, tax-
exempt association.

ATTENTION: INSTITUTIONAL BIOSAFETY COMMITTEE CHAIR OR MANAGER

John D. Morrey
Utah State University, College of Agriculture
Department of Animal, Dairy and Veterinary Sciences
Institute for Antiviral Research
5600 University Blvd.
Logan UT 84322-5600

By fax: (435) 797-2766

REQUEST FOR PUBLIC DOCUMENTS UNDER THE NIH GUIDELINES

Pursuant to the NIH Guidelines on Research Involving Recombinant DNA Molecules, the Sunshine Project hereby requests the following records in the possession of Utah State University:

1. All minutes of all meetings of the Utah State University Institutional Biosafety Committee from 1 June 2003 through the present date.

The Sunshine Project expects to receive the minutes by 8 June 2004. Please send your reply to:

Edward Hammond
The Sunshine Project
101 West 6th Street, Suite 607
Austin TX 78701

In addition, please read and consider the following very carefully:

- Almost four months ago, The Sunshine Project requested IBC minutes from Utah State University. Utah State University did not reply to that request.
- Under the NIH Guidelines, you must make the requested meeting minutes available to the Sunshine Project. In failing to reply, Utah State University is not in compliance with the NIH Guidelines.
- The Sunshine Project hopes that you will fulfill your obligation and honor this request. If the Sunshine Project does not receive access to the requested minutes by the requested date, a complaint will be filed against Utah State University with the NIH Office of Biotechnology Activities. Your failure to reply will also be cited in a public report.

Sincerely,



Edward Hammond
Director

**Institutional Biosafety Committee for Recombinant DNA
Committee Meeting Minutes
February 23, 2004**

- I. Attendance
John Morrey, Chair, Anne Anderson, Salam M. Awada, Dennis Odell, Kirt Poulsen, Vernon Summers
- II. Committee Organization
 - a. Who should be on the committee
A copy of the information addressing committee membership requirements from the NIH Guidelines for Research Involving Recombinant DNA Molecules was distributed to the committee. The guidelines indicate the committee should be comprised of no fewer than five members and that two of the members should not be affiliated with the institution.
 - b. Introductions
Dr. Morrey introduced each member of the committee and discussed their role on the committee.
Dr. John Morrey: Chair and animal research representative
Anne Anderson: Plant research representative
Salam M. Awada: Community representative
Dr. Dennis Odell: Human research representative
Kirt Poulsen: Biological Safety Officer
Vernon Summers: Community representative
- III. Explain format of NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)
 - a. Biosafety in Microbiological and Biomedical Laboratories
This is a safety manual produced by the CDC and NIH which addresses safety work practices and biosafety level (BSL)1-4 containment in microbiological and biomedical laboratories. A summary of this manual can be found in Appendix G of the NIH Guidelines.
 - b. NIH Guidelines table of contents
The table of contents for the NIH Guidelines were given to each member of the committee. Information in the NIH Guidelines for sections 1-5 and appendices A-Q was discussed using the table of contents as a guide.
- IV. Issues and problems with current organization
- V. Review projects
A list of the all projects approved by the committee will be sent to each committee member of review by Barbara Stuart.
- VI. Proposed assignments

- a. Appendix A - Natural exchangers
- b. Appendix B - Classification of Human Etiological Agents on the Basis of Hazard
- c. Appendix E - Certified Host-Vector Systems (What is the purpose of Certifying Host-Vector systems?)
- d. Appendix I - Biological containment of Host-Vector systems
- e. Appendix K - Large Scale Production
- f. Search USDA site for categorization of organisms in regards to containment

Action Items

- 1. Ask RAC for clarification about Host-Vector system. (Anne Anderson)
- 2. Talk with Vice President for Research about requiring all grants to fill out a SPO-1 form. Currently there are grants that are not required to fill out the SPO-1 form. (John Morrey)
- 3. Send a pdf file of Appendix P to all approved principle investigators conducting recombinant DNA research with plants. (Barbara Stuart)
- 4. Send a memo from the Vice President for Research to all department heads asking for names of any principle investigator conducting recombinant DNA research in their department. (John Morrey)
- 5. Send a copy of the CDC / NIH biosafety manual to each principle investigator conducting biological research. Inform each principle investigator that the manual contains information regarding proper design and work practices in BSL 1-4 laboratories.
- 6. Determine a method of dealing with the risk to students in teaching labs that may be immuno-compromised.



the sunshine project

101 West 6th Street, Suite 607 Austin TX 78701 USA

Tel/Fax: +1 512 494 0545

<http://www.sunshine-project.org>

7 July 2004

ADVISORY COMMITTEE

Ignacio Chapela
Berkeley, United States

Chee Yoke Ling
Kuala Lumpur, Malaysia

Julian Perry Robinson
Brighton, United Kingdom

Tewolde Berhan Gebre Egziabher
Addis Ababa, Ethiopia

Christine von Weizsäcker
Bonn, Germany

Mark Wheelis
Davis, United States

GERMAN OFFICE

The Sunshine Project
Scheplerstrasse 78
22767 Hamburg

Tel: +49 40 431 88 001
Fax: +49 40 675 03 988

The Sunshine Project US is a
501(c)3 non-profit organization.
Donations are tax-deductible.

The Sunshine Project Germany
(e.V.) is a federally recognized, tax-
exempt association.

John D. Morrey
Utah State University, College of Agriculture
Department of Animal, Dairy and Veterinary Sciences
Institute for Antiviral Research
5600 University Blvd.
Logan UT 84322-5600
By fax: (435) 797-2766

Dear Dr. Morey,

In late January I initial wrote you and requested, pursuant to the NIH Guidelines, the minutes of the two most recent meetings of the Utah State University Institutional Biosafety Committee (USU IBC). You did not reply to that request.

On 24 May 2004, I again wrote to you and again requested USU IBC minutes, again citing the NIH Guidelines. You replied by providing the minutes of one meeting, that of 23 February 2004. The minutes of this meeting appear to reflect that it is the first that has ever occurred at USU. Yet, when I consult NIH grant abstracts, I can see that USU has received NIH funding for recombinant DNA research for some time.

t your February meeting, you did not review any protocols; but, oddly, the minutes note that "*A list of all projects approved by the committee will be sent to each committee member of review.*" They also reflect the fact that there appear to be numerous rDNA projects at USU of which the IBC has not been advised.

This letter is a final request for further information from USU. **Pursuant to the NIH Guidelines, the Sunshine Project requests all minute of all meeting of the USU IBC, from 1 January 2001 through the present date.**

If the IBC has not been meeting, or has not existed, please explain why.

In view of the fact that the Sunshine Project has been requesting information about the USU IBC for five months and has received very little in reply, **I wish to advise you that in order to avoid a formal complaint to NIH OBA, the deadline for an adequate reply from USU to arrive in my offices is Monday July 12th.**

Thank you very much for your prompt attention to this matter.

Sincerely,



Edward Hammond
Director

cc: Dr. Amy Patterson, NIH OBA
Mr. Steve Erickson, Citizens Education Project, Salt Lake City

Utah State UNIVERSITY

COLLEGE OF AGRICULTURE
Department of Animal, Dairy and Veterinary Sciences
5600 Old Main Hill
Logan UT 84322-5600
Phone: (435) 797-1880
FAX: (435) 797-3959


August 24, 2004

Edward Hammond, Director
The Sunshine Project
101 West 6th Street
Suite 607
Austin TX 78701

Dear Mr. Hammond:

Enclosed is the list of projects referred to in the minutes previously sent for recombinant DNA research.

Sincerely,

A handwritten signature in black ink, appearing to read "J. Morrey", is written over the typed name.

John Morrey, Chairman

cc: Brent Miller
Craig Simper
Russ Price

DNA Committee

Date	PI	Project	Containment	Location
4-10-03	John Carman	Cloning Genes Associated with Apomixis in Angiosperms	BL-1P	PSB
1-23-03	Ronald Sims	Dioxgenase Mycobacteria Gene Probe	BSL-1	Water Resources Lab
2000 2001 1-23-03	Paul Johnson	Transgenic Kentucky bluegrass Field evaluation of glyphosate resistant Kentucky bluegrass Field trial of grass from company Gene Flow between Western U.S. Poa-Bluegrass	BSLP-1 discontinued in progress	PSB
12-16-02	Ilka Nemere	Regulation of Intestinal Phosphate Absorption	BL-1P	NFS
9-17-02	Yajun Wu	Identification of Novel Cell Wall Protein Genes in Arabidopsis	BL-1P	PSB
7-22-02	John Morrey	Molecular Clones (Plasmids) of West Nile Virus & Japanese Encephalitis Virus	BSL-3	Biology - VSB 318 & LARC BL-3 Lab
1998/2002/ 2003 2002 2001 2001 1998/2001	Daryll DeWald	The role of phosphoinositide signaling in plant stress acclimation The metastasis suppressor BRMS1 alters ... Regulation of cardiac fibroblast metalloproteinase secretion Phosphoinositide regulation of protein secretion The role phosphatidylinositol 4-kinase in breast cancer metastasis	BL-1/BL-1P previously approved BL-1 BL-1 BL-1	Biology
1-24-02	Michelle Grilley	Modification of Saccharomyces Cerevisiae Syr2p	BL-1	Biology
3-9-01	Scott Ockey	Leaves Infection by Erwinia Amplovora	BL-1P	Biology
2000 2000 2000 2001 2001 2001 2001	Morrey/Julander John Morrey	Hepatitis C in cell culture Hepatitis B virus infectious genome Development of an immobilized system to aid protein folding Transgenic mouse production Transgenic Mice for Anti-Scrapie Therapeutics Molecular work with infection clone of Japanese encephalitis virus Prion transgenic mice	BL-2 BL-2 BL-1 BL-1N BL-1N BL-3 BL-1	ADVS-LARC
2001 2000 2002 2002 2001	Jeff Broadbent	Gene Cloning - Lactic Acid Bacteria Influence of starter proteinases specificity on bitterness in cheddar cheese A genomics approach to understanding lactic Systematic identification of lactobacillus... Cheese starter proteinase	BL-1 BL-1 Previously approved Previously approved BL-1	NFS
3-15-02	Jason Roth Dale Barnard	HPIV-3 Cloning (Human Parainfluenza Virus Type 3)	BL-2	ADVS
1998 8-24-01	John Peters Peters/Lemon	Structural analysis of the gene products involved in FeMo-cofactor biosynthesis Reversible hydrogen oxidation catalyzed by an iron-only hydrogenase from clostridium pasteurianum	BL-1 BL-1	Chem
11-2-01	Paul Wolf William D. Speer		BL-1	Biology
2001 8-9-01	Ken White	Production of proteins in transgenic animals Transgenic Rabbits Producing Human Immunoglobulins	BL-1N BL-1N	ADVS
1998 2000 2001 2001	Noelle Cockett	Characterization of ovine genome Characterization of the gene responsible for spider lamb syndrome in sheep Identification of genetic markers associated with economically important traits in livestock Development of a whole-genome radiation hybrid map for sheep Fine mapping of QTL's associated with resistance to nematode infection in sheep	BL-1 BL-1 BL-1 BL-1 BL-1	ADVS
2000 2001	Ensign/Clark Scott Ensign	Characterization of two flavoproteins central to aliphatic epoxide metabolism in Xanthobacter strain Py2 and Rhodococcus Microbial metabolism of aliphatic alkenes	BL-1 BL-1	

2000	Barnard/Pence	Cloning and expressing mink IL-2 gene in baculovirus expression system	BL-1	ADVS
2000	Keven Jackson	Friend murine leukemia virus genome	BL-2	ADVS
2000	Lance Seefelt	Nucleotide-dependent energy transduction in nitrogenase	BL-1	
2001	Brett Adams	RGS proteins and neuronal calcium channel modulation	exempt	
1998	Marie Walsh	Development of an immobilized system to aid protein folding	BL-1	
1998	David Hole	UTW98-1 Improved high molecular weight glutenins	BLP-1	
1998	Coulombe/Hole	Detoxification of aflatoxin in maize in situ	BLP-1	